Position in ABUS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$0
-$96,200 QoQ
Shares Held
0
-100.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2022
6 quarters on record
Common Shares in ABUS Over Time
Shares Held
Position Value (USD)
Derivatives in ABUS
reported options exposure · as of Mar 31, 2026CallValue
$135,000
CallShares
30,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Verition Fund Management LLC holds $152,220,097 across 64 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TECH |
BIO-TECHNE Corp
|
438,746 | $30,997,404 | |
| 2 | APGE |
Apogee Therapeutics, Inc.
|
159,256 | $21,138,048 | |
| 3 | ABVX |
Abivax S.A.
|
105,791 | $14,097,708 | |
| 4 | IDYA |
IDEAYA Biosciences, Inc.
|
184,054 | $6,859,692 | |
| 5 | SNDX |
Syndax Pharmaceuticals Inc
|
304,939 | $6,665,966 | |
| 6 | MRVI |
Maravai Lifesciences Holdings, Inc.
|
777,738 | $4,853,085 | |
| 7 | CYTK |
Cytokinetics Inc
|
54,889 | $4,675,993 | |
| 8 | RPRX |
Royalty Pharma plc
|
75,000 | $4,205,250 |
All Filings in ABUS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $135,000 | 30,000 | Call | Sole | 2026-05-15 | |
| 2025-12-31 | $96,200 | 20,000 | Shares | Sole | 2026-02-13 | |
| 2024-06-30 | $73,934 | 23,927 | Shares | Sole | 2024-08-14 | |
| 2023-03-31 | $76,874 | 25,371 | Shares | Sole | 2023-05-15 | |
| 2022-09-30 | $21,031 | 11,011 | Shares | Sole | 2023-01-18 | |
| 2022-06-30 | $28,213 | 10,411 | Shares | Sole | 2022-08-30 | |
| No filing history on record for this holder in this stock. | ||||||